Abstract: SA-PO929
High-Density Lipoprotein Lipidomics and Risk of Mortality in CKD
Session Information
- CKD: Observational Research and Patient-Oriented Interventions
November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2202 CKD (Non-Dialysis): Clinical‚ Outcomes‚ and Trials
Authors
- Lidgard, Benjamin, University of Washington, Seattle, Washington, United States
- Hoofnagle, Andrew N., University of Washington, Seattle, Washington, United States
- Zelnick, Leila R., University of Washington, Seattle, Washington, United States
- Kestenbaum, Bryan R., University of Washington, Seattle, Washington, United States
- de Boer, Ian H., University of Washington, Seattle, Washington, United States
- Robinson-Cohen, Cassianne, Vanderbilt University Medical Center, Nashville, Tennessee, United States
- Fretts, Amanda M., University of Washington, Seattle, Washington, United States
- Lemaitre, Rozenn, University of Washington, Seattle, Washington, United States
- Bansal, Nisha, University of Washington, Seattle, Washington, United States
Background
Patients with CKD are at higher risk for mortality compared to the general population. Abnormalities in the structure and function of high-density lipoprotein (HDL) may contribute to this increased risk. We isolated HDL and utilized targeted lipidomics to identify its ceramide, sphingomyelin, and phosphatidylcholine components in participants with CKD and examined adjusted associations between these lipids and mortality.
Methods
We studied 498 participants with CKD from the Seattle Kidney Study. In each participant, HDL was isolated from serum, and targeted lipidomics were used to identify levels of various ceramides, sphingomyelins, and phosphatidylcholines composing HDL. We evaluated the associations between each lipid and mortality using Cox regression adjusted for potential confounders, accounting for multiple comparisons at a false discovery rate of 5%.
Results
Over a median (IQR) follow-up time of 5.9 (3.4, 8.9) years, there were 168 deaths. After adjustment, higher HDL composition of ceramide 24:2, glucosylceramide 16:0, and sphingomyelin 16:0 were significantly associated with death (HR per standard deviation greater lipid concentration, 95% CI; 1.31, 1.14-1.51; 1.25, 1.08-1.46; and 1.22, 1.07-1.40; respectively) (Figure).
Conclusion
After adjustment, higher HDL concentrations of ceramide 24:2, glucosylceramide 16:0, and sphingomyelin 16:0 were significantly associated with risk of death in patients with CKD. Further studies investigating functional significance for these findings may direct development of future therapies.
Funding
- NIDDK Support